What 2018 Attendees Had to Say
"I really enjoyed the speakers and the networking. It was great to exchange ideas at the round table discussion and meet other people with similar concerns about tumor models"
Shawnya Michaels, VP, Scientific Affairs, Escend Pharmaceuticals, Inc
"The conference was very informative. I especially enjoyed the pre-conference workshops. I learned a great deal about the pros and cons of the models used for immunotherapy."
Joan M. Chapdelaine, Senior Director, Immunology, Calvert Laboratories, Inc.
"The conference gave me an opportunity to delve deeper into our current in vivo models and start to identify areas to improve and develop better assays. It was also a good space to meet new people in the industry as it gets bigger and more complex."
Connie Ardila, Xencor
"The meeting was a great mix of new technologies and scientific insight into solving some of the major problems in this area."
Kate Blease, Senior Director, Celgene
"It was a great chance to learn about new research from colleagues and new vendor offerings to support the research--well worthwhile."
Rachel Dusek, Senior Director of Preclinical Development, Oxford BioTherapeutics
"This was a great meeting for networking and exchanging technological troubles with colleagues. I did learn a lot of useful stuff for my experiments. There was a very nice collaborative spirit!"
Elsa Quintana, Associate Director, Revolution Medicines
"It was an excellent conference where the relative small number of participants created a great atmosphere for discussion and scientific exchange."
Damien Bresson, Associate Director, Sorrento therapeutics